Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.63+0.09 (+1.19%)
Close on Nov 18, 2026Market cap $44.12MP/E –Yield –
Xilio Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Xilio Therapeutics's price to book ratio was 0.8× on Nov 11, 2026, against 5.1× a year earlier. Over the last 5 years it ranged from 0.3× to 6.2×, with a median of 0.9×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.8× | −5.1 |
| 2025 | Oct 31, 2025 | 5.8× | +3.8 |
| 2024 | Dec 31, 2024 | 2.0× | +1.7 |
| 2023 | Dec 29, 2023 | 0.3× | −0.3 |
| 2022 | Dec 30, 2022 | 0.6× | – |
See a number that looks wrong?